Security Snapshot

Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) Institutional Ownership

CUSIP: 87184Q107

13F Institutional Holders and Ownership History from Q2 2016 to Q2 2023

Latest Period

n/a

Institutions Reporting

Shares (Excl. Options)

Price

Save this security research path

Keep this CUSIP in your research flow, then return after the next filing cycle to check what changed.

Create free account to save this research Review latest holder period
Type / Class
Equity / Common Stock, $0.001 par value
Symbol
SYRS on Nasdaq
Shares outstanding
27,995,500
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Sponsored

Quick Takeaways

  • SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value is tracked under CUSIP 87184Q107.
  • Latest finished 13F holder period is not available.
  • 1 significant owner is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 1 to 0 between Q1 2023 and Q2 2023.
  • Reported value moved from $585 to $0.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Official SEC Source

Backed by Schedule 13D/13G

Ownership context comes from SEC Form 13F and, when available, Schedule 13D/13G filings.

See Original Filing

Investment Quick Answers

What is CUSIP 87184Q107?
CUSIP 87184Q107 identifies SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Significant Owners of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Invus Global Management, LLC 3.8% $776,595 1,063,829 Invus Public Equities, L.P. 31 Dec 2024

Institutional Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2023 Q2 0 $0 -$585 0
2023 Q1 219 $585 $2.67 1
2022 Q4 219 $786 -$5,677,000 $3.59 1
2022 Q3 881,719 $5,679,000 -$38,920,523 $6.44 3
2022 Q2 35,563,928 $34,226,317 -$9,550,880 $0.96 58
2022 Q1 44,600,309 $53,054,739 -$16,229,688 $1.19 86
2021 Q4 51,167,771 $165,935,422 +$2,424,541 $3.26 84
2021 Q3 47,185,070 $209,928,186 -$4,801,116 $4.47 92
2021 Q2 47,939,973 $259,937,712 -$108,395,908 $5.45 95
2021 Q1 60,879,549 $453,765,087 +$51,303,227 $7.48 99
2020 Q4 53,645,472 $580,176,544 +$89,474,242 $10.85 99
2020 Q3 46,027,616 $405,893,308 +$16,189,114 $8.84 91
2020 Q2 39,975,459 $425,248,905 +$6,981,050 $10.66 77
2020 Q1 44,878,307 $265,481,374 +$15,181,069 $5.93 63
2019 Q4 42,159,417 $290,644,730 -$8,983,413 $6.91 70
2019 Q3 43,076,602 $446,224,216 +$88,973,322 $10.38 61
2019 Q2 31,644,913 $291,721,875 +$102,579,332 $9.26 66
2019 Q1 20,623,242 $188,494,058 +$16,131,561 $9.14 63
2018 Q4 22,234,612 $123,844,000 +$995,029 $5.57 67
2018 Q3 17,416,778 $207,439,026 +$2,479,368 $11.91 73
2018 Q2 17,226,749 $175,885,142 +$16,540,742 $10.21 73
2018 Q1 18,506,513 $240,212,598 +$38,686,687 $12.98 54
2017 Q4 15,877,766 $154,493,194 +$4,671,125 $9.73 68
2017 Q3 12,031,237 $177,159,772 +$16,405,535 $14.72 66
2017 Q2 10,799,619 $173,764,545 +$43,612,075 $16.09 45
2017 Q1 12,887,128 $205,289,593 +$2,132,231 $15.93 42
2016 Q4 12,922,246 $157,133,459 +$1,761,438 $12.16 40
2016 Q3 12,757,094 $176,293,302 +$3,959,949 $13.87 34
2016 Q2 7,667,574 $119,948,000 +$119,948,000 $18.15 11

Sponsored